Literature DB >> 6734052

Digoxin-quinidine-spironolactone interaction.

P E Fenster, W D Hager, M M Goodman.   

Abstract

Digoxin kinetics are substantially altered by quinidine and by spironolactone. We evaluated the effect of the combination of quinidine and spironolactone on digoxin kinetics and compared it to the effect on digoxin of each drug alone. Six normal subjects each received a 1.0-mg intravenous dose of digoxin alone, digoxin with quinidine, digoxin with spironolactone, and digoxin with both quinidine and spironolactone. Spironolactone and quinidine, alone and in combination, reduced digoxin systemic, renal, and nonrenal clearances and prolonged digoxin elimination t 1/2. A greater alteration in digoxin kinetics was induced by quinidine than by spironolactone, and an even greater effect resulted from the combination. We did not assess clinical consequences of the interaction. We advise reduction in digoxin dose, careful clinical evaluation, and measurement of serum digoxin concentrations when digoxin is used in combination with quinidine and spironolactone.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6734052     DOI: 10.1038/clpt.1984.141

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  14 in total

1.  Use of different parameters and equations for calculation of IC₅₀ values in efflux assays: potential sources of variability in IC₅₀ determination.

Authors:  Donna A Volpe; Salaheldin S Hamed; Lei K Zhang
Journal:  AAPS J       Date:  2013-12-13       Impact factor: 4.009

Review 2.  Pharmacokinetic interactions with digoxin.

Authors:  S M Rodin; B F Johnson
Journal:  Clin Pharmacokinet       Date:  1988-10       Impact factor: 6.447

Review 3.  Renal Drug Transporters and Drug Interactions.

Authors:  Anton Ivanyuk; Françoise Livio; Jérôme Biollaz; Thierry Buclin
Journal:  Clin Pharmacokinet       Date:  2017-08       Impact factor: 6.447

Review 4.  Pharmacokinetic drug interactions between digoxin and antiarrhythmic agents and calcium channel blocking agents: an appraisal of study methodology.

Authors:  E M Antman; J M Arnold; P L Friedman; T W Smith
Journal:  Cardiovasc Drugs Ther       Date:  1987-08       Impact factor: 3.727

Review 5.  Clinical pharmacokinetic significance of the renal tubular secretion of digoxin.

Authors:  G Koren
Journal:  Clin Pharmacokinet       Date:  1987-11       Impact factor: 6.447

6.  Population pharmacokinetics of digoxin in Japanese patients: a 2-compartment pharmacokinetic model.

Authors:  E Yukawa; F Suematu; M Yukawa; M Minemoto; S Ohdo; S Higuchi; Y Goto; T Aoyama
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

7.  Digoxin-interactions in man: spironolactone reduces renal but not biliary digoxin clearance.

Authors:  A Hedman; B Angelin; A Arvidsson; R Dahlqvist
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 8.  Cardiac glycosides. Drug interactions of clinical significance.

Authors:  B Magnani; P L Malini
Journal:  Drug Saf       Date:  1995-02       Impact factor: 5.606

Review 9.  Drug-related arrhythmias during therapy of congestive heart failure.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1987-08       Impact factor: 3.727

10.  Gender differences, polypharmacy, and potential pharmacological interactions in the elderly.

Authors:  Carina Duarte Venturini; Paula Engroff; Luísa Scheer Ely; Luísa Faria de Araújo Zago; Guilherme Schroeter; Irenio Gomes; Geraldo Attilio De Carli; Fernanda Bueno Morrone
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.